The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.

Glucose reabsorption is mediated by the sodium-glucose cotransporter (SGLT) 2, which reabsorbs 90% of glucose, and SGLT1, which reabsorbs the remaining 10%.

The relationship between hyperglycaemia and the development of renal disease is complex. Hyperglycaemia-induced complications are mediated by several metabolic pathways, among which accumulation of Advanced Glycation End-products with abnormalities of the glycosylation of macromolecules and increased glucose flux through the polyol pathway seem to be the most important.

Inclusion Criteria:

• Age ≥ 18 years.
• Both sexes.
• Chronic kidney disease (CKD) participants with stages 3 and 4.

Exclusion Criteria:

• Patients with type 1 diabetes mellitus (DM).
• Patients with decompensated Chronic liver disease.
• Patients with uncontrolled hypertension.
• Patients with blood pressure (BP) > 110/70.
• Patients already on the same medication (Sodium Glucose Co-Transporter 2 Inhibitors).
• Patients with a history of recurrent or recent urinary tract infection (UTI).
• Patients with glycated hemoglobin (HbA1c) ≤10.
• Adult polycystic kidney disease.
• All patients on immunosuppressive medications.

This case-control study was done on 60 adult chronic kidney disease (CKD) individuals with stage 3 and 4 (eGFR>_20ml/min/1.73 m2) according to KIDGO classification at Ain Shams University Hospitals, Cairo, Egypt.

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

After the end of study for one year.

The data will be available upon a reasonable request from the corresponding author.